Achieve Life Sciences (NASDAQ:ACHV) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.18), Fidelity Earnings reports.
Achieve Life Sciences stock traded up $0.93 on Friday, hitting $3.38. The company’s stock had a trading volume of 9,439,966 shares, compared to its average volume of 1,721,912. The firm has a market capitalization of $16.33 million, a PE ratio of -0.15 and a beta of 2.75. Achieve Life Sciences has a one year low of $1.04 and a one year high of $14.60.
Separately, Zacks Investment Research raised shares of Achieve Life Sciences from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Thursday, November 15th.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.
Read More: Why is the price-sales ratio important?
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.